These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15588066)

  • 21. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome.
    Pierangeli SS; Vega-Ostertag ME; González EB
    Expert Rev Mol Med; 2007 Nov; 9(30):1-15. PubMed ID: 17997880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations.
    Blank M; Shoenfeld Y
    Clin Immunol; 2004 Aug; 112(2):190-9. PubMed ID: 15240163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical consequences of antiphospholipid antibodies.
    Derksen RH; de Groot PG
    Neth J Med; 2004 Sep; 62(8):273-8. PubMed ID: 15588067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelets and the antiphospholipid syndrome.
    Urbanus RT; Derksen RH; de Groot PG
    Lupus; 2008 Oct; 17(10):888-94. PubMed ID: 18827053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European attempts for the standardisation of the antiphospholipid antibodies.
    Tincani A; Filippini M; Scarsi M; Galli M; Meroni PL
    Lupus; 2009 Sep; 18(10):913-9. PubMed ID: 19671792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of beta 2-glycoprotein I in the antiphospholipid syndrome.
    Krilis SA; Sheng YH; Kandiah DA
    Lupus; 1996 Apr; 5(2):150-2. PubMed ID: 8743129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.
    Pierangeli SS; Chen PP; Raschi E; Scurati S; Grossi C; Borghi MO; Palomo I; Harris EN; Meroni PL
    Semin Thromb Hemost; 2008 Apr; 34(3):236-50. PubMed ID: 18720303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation.
    Adams M
    Semin Thromb Hemost; 2008 Apr; 34(3):251-5. PubMed ID: 18720304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests.
    Galli M; Barbui T
    Semin Thromb Hemost; 2005 Feb; 31(1):17-24. PubMed ID: 15706471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation.
    Rahgozar S; Yang Q; Giannakopoulos B; Yan X; Miyakis S; Krilis SA
    Arthritis Rheum; 2007 Feb; 56(2):605-13. PubMed ID: 17265495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the antiphospholipid syndrome and its treatment.
    Arnout J; Jankowski M
    Curr Hematol Rep; 2005 Sep; 4(5):385-90. PubMed ID: 16131440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiphospholipid antibodies: involvement of protein cofactors.
    Galli M; Barbui T; Zwaal RF; Comfurius P; Bevers EM
    Haematologica; 1993; 78(1):1-4. PubMed ID: 8491417
    [No Abstract]   [Full Text] [Related]  

  • 33. [Physiopathology of autoimmune diseases--recent findings. 3) Antiphospholipid antibody syndrome].
    Ichikawa K; Tsutsumi A; Atsumi T; Matsuura E; Koike T
    Nihon Naika Gakkai Zasshi; 1998 Sep; 87(9):1729-34. PubMed ID: 9816839
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiphospholipid antibodies and the protein C pathway.
    Urbanus RT; de Laat B
    Lupus; 2010 Apr; 19(4):394-9. PubMed ID: 20353976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography.
    Devreese K; Peerlinck K; Arnout J; Hoylaerts MF
    Thromb Haemost; 2009 Jan; 101(1):185-96. PubMed ID: 19132207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke.
    Kahles T; Humpich M; Steinmetz H; Sitzer M; Lindhoff-Last E
    Rheumatology (Oxford); 2005 Sep; 44(9):1161-5. PubMed ID: 15927998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.
    Asherson RA; Cervera R; Merrill JT; Erkan D
    Semin Thromb Hemost; 2008 Apr; 34(3):256-66. PubMed ID: 18720305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism.
    de Laat B; Mertens K; de Groot PG
    Nat Clin Pract Rheumatol; 2008 Apr; 4(4):192-9. PubMed ID: 18285765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticardiolipin and anti-beta-2-glycoprotein I antibodies.
    Marai I; Tincani A; Balestrieri G; Shoenfeld Y
    Autoimmunity; 2005 Feb; 38(1):33-8. PubMed ID: 15804703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome.
    Meroni PL; Raschi E; Camera M; Testoni C; Nicoletti F; Tincani A; Khamashta MA; Balestrieri G; Tremoli E; Hess DC
    J Autoimmun; 2000 Sep; 15(2):237-40. PubMed ID: 10968917
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.